# BPC-157

Canonical source: https://retacompare.com/encyclopedia/bpc-157

Up-regulates VEGF-R2 / NO pathways and modulates dopamine, GABA, serotonin systems; promotes angiogenesis, fibroblast migration, tendon-to-bone healing in animal models.

Reference facts

Also known asBody Protection Compound 157, PL 14736CategoryHealing & Tissue RepairMechanism of actionUp-regulates VEGF-R2 / NO pathways and modulates dopamine, GABA, serotonin systems; promotes angiogenesis, fibroblast migration, tendon-to-bone healing in animal models.TargetsVEGF-R2 (indirect), NO synthesis, Multiple growth factor pathwaysIndications under research or approvedResearch only — tendon, ligament, GI ulcer, IBD models in animalsRegulatory status (reference entry)Not FDA-approved. Removed from FDA 503A bulks list 2023.Half-life~4 hours (oral, gastric stability)SequenceGEPPPGKPADDAGLVSequence notes15-residue partial sequence of human gastric juice protein BPC. Stable acetate or arginate salt commonly used in research.Molecular weight (Da)1419Originator / sponsorOriginally Diagen / Pliva (Croatian research)First reported1991OriginIsolated from human gastric juice by Predrag Sikiric and colleagues at the University of Zagreb.
    Primary References

Sikiric et al., Curr Pharm Des 2014 (BPC-157 review)

FDA 503A bulks list — BPC-157 nominated for category 2 (insufficient safety data)


    Explore research articles about BPC-157


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Sikiric et al., Curr Pharm Des 2014 (BPC-157 review): https://pubmed.ncbi.nlm.nih.gov/23092289/
- FDA 503A bulks list — BPC-157 nominated for category 2 (insufficient safety data): https://www.fda.gov/drugs/human-drug-compounding/category-2-bulk-drug-substances-fda-has-significant-safety-risk-concerns